See up to 3 months of TRXB. The 7-day demo opens the 1M and 3M ranges and puts TRXB on your watchlist.
Start 7-day demoLatest TRXB insider trades
About TRex Bio, Inc. (TRXB)
Trex Bio Inc is a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases.
- 2026
- XNAS
TRXB Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 92,857 | $1.30M |
| Grant or award | 6 | 105,000 | |
| Other acquisition / disposition | 12 | 5,782,885 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
TRXB insider transactions (Form 4)
208 Form 4 filings on record, the earliest from Oct 9, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Joel S. Marcus - Director | Other | Common Stock | 41,871 | - footnote F1 | - | |
| Joel S. Marcus - Director | Other | Series B Convertible Preferred Stock | 161,828 | $0.00 | - | |
| ||||||
| SVLSF VI, LLC - 10% Owner | Open-market purchase | Common Stock | 89,783 | $14.00 | $1.26M | |
| SVLSF VI, LLC - 10% Owner | Other | Common Stock | 1,574,074 | $0.00 | - | |
| SVLSF VI, LLC - 10% Owner | Other | Common Stock | 475,411 | $0.00 | - | |
| SVLSF VI, LLC - 10% Owner | Open-market purchase | Common Stock | 3,074 | $14.00 | $43K | |
| SVLSF VI, LLC - 10% Owner | Other | Common Stock | 53,892 | $0.00 | - | |
| SVLSF VI, LLC - 10% Owner | Other | Common Stock | 16,277 | $0.00 | - | |
| SVLSF VI, LLC - 10% Owner | Other | Common Stock | 669,939 | $0.00 | - | |
| SVLSF VI, LLC - 10% Owner | Other | Series A Preferred Stock | 1,574,074 | $0.00 | - | |
| SVLSF VI, LLC - 10% Owner | Other | Series B Preferred Stock | 475,411 | $0.00 | - | |
| SVLSF VI, LLC - 10% Owner | Other | Series A Preferred Stock | 53,892 | $0.00 | - | |
| SVLSF VI, LLC - 10% Owner | Other | Series B Preferred Stock | 16,277 | $0.00 | - | |
| SVLSF VI, LLC - 10% Owner | Other | Series B Preferred Stock | 669,939 | $0.00 | - | |
| Joel S. Marcus - Director | Grant or award | Stock Option (Right to Buy) | 17,500 | $0.00 | - | |
| Travis Alan Coy - Director | Grant or award | Stock Option (Right to Buy) | 17,500 | $0.00 | - | |
| Michael Jay Ross - Director | Grant or award | Stock Option (Right to Buy) | 17,500 | $0.00 | - | |
| Peter Hirth - Director | Grant or award | Stock Option (Right to Buy) | 17,500 | $0.00 | - | |
| Carol Giltner Gallagher - Director | Grant or award | Stock Option (Right to Buy) | 17,500 | $0.00 | - | |
| Julie Ann Gilmore - Director | Grant or award | Stock Option (Right to Buy) | 17,500 | $0.00 | - | |
TRXB insider trading FAQ
What is the latest insider trade for TRXB?
TRex Bio, Inc. (TRXB) had 8 insider filings in the last 90 days, with the most recent on 2026-10-13. The full record for TRXB runs to 8 Form 4 filings, the earliest from 2026-10-09. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying TRXB stock?
2 insider purchases of TRXB were filed in the last 90 days, totaling $1.30M.
How many insiders are selling TRXB stock?
No insider sales of TRXB were filed in the last 90 days.
Where can I see TRXB SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects TRXB Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
8The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Joel S. Marcus view on EDGAR
- - SVLSF VI, LLC view on EDGAR
- - Joel S. Marcus view on EDGAR
- - Travis Alan Coy view on EDGAR
- - Michael Jay Ross view on EDGAR
- - Peter Hirth view on EDGAR
- - Carol Giltner Gallagher view on EDGAR
- - Julie Ann Gilmore view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where TRXB's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow TRXB with a 7-day demo
- TRXB on your watchlist
- Every TRXB Form 4 filing on record
- Up to 3 months of TRXB price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
